IN8bio Issues Stock Inducement Grant Under Nasdaq Rule 5635(c)(4)
IN8bio has disclosed a stock inducement grant to a new employee under Nasdaq's equity compensation listing rules.
IN8bio, a clinical-stage biopharmaceutical company, has disclosed an equity inducement grant awarded to a newly hired employee, the company announced via GlobeNewswire. The grant was issued in compliance with Nasdaq Listing Rule 5635(c)(4), which permits companies to award equity compensation to new hires without prior shareholder approval under specific conditions.
Nasdaq's Rule 5635(c)(4) is a commonly used provision that allows publicly listed companies to grant stock options or other equity awards as an inducement for prospective employees to join the firm. The rule is designed to give companies flexibility in recruiting talent by offering equity as part of compensation packages.
Read more SEC Pursues Final Judgment Against Former Western Asset Co-CIO Ken Leech →
IN8bio, which focuses on gamma-delta T cell therapies for cancer treatment, routinely reports such grants to maintain transparency with shareholders and regulators. Inducement grants are a standard tool in the biopharmaceutical sector, where competition for specialized scientific and clinical talent remains intense.
The company did not disclose the specific terms of the grant, including the number of shares, strike price, or the identity of the recipient, in the announcement summary available. Investors seeking full details are advised to review the company's formal filing with the Securities and Exchange Commission.
Continue reading at GlobeNewswire - Industry News on Financial Services.
